Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma

Journal of Urology

Volumn 177, Issue 1, 2007, Pages 84-89

  Lin, Chia Chi ^a,b   Hsu, Chih Hung ^a,b   Huang, Chao Yuan ^a   Cheng, Ann Lii ^a,b   Vogelzang, Nicholas J ^c   Pu, Yeong Shiau ^a  

^a Department of Oncology ^*  (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

bladder; carcinoma; cytotoxins; neoplasm metastasis; toxicity; transitional cell; urothelium

Indexed keywords

ANTIEMETIC AGENT; BETAMETHASONE; CISPLATIN; CREATININE; DIPHENHYDRAMINE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MALE; METASTATIC UROTHELIAL CARCINOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PACLITAXEL; URINARY BLADDER NEOPLASMS; VITAMIN B COMPLEX;

EID: 33845342862     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.08.058     Document Type: Article

References (24)

1. Roth B.J., and Bajorin D.F. Advanced bladder cancer. the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 153 (1995) 894
2. Saxman S.B., Propert K.J., Einhorn L.H., Crawford E.D., Tannock I., Raghavan D., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma. a cooperative group study. J Clin Oncol 15 (1997) 2564
3. Logothetis C.J., Dexeus F.H., Finn L., Sella A., Amato R.J., Ayala A.G., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8 (1990) 1050
4. vonderMaase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602
5. Bajorin D.F., Dodd P.M., Mazumdar M., Fazzari M., McCaffrey J.A., Scher H.I., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17 (1999) 3173
6. Cheng A.L., Yeh K.H., Lin J.T., Hsu C., and Liu M.Y. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)-a very effective regimen with good patients' compliance for advanced gastric cancer. Anticancer Res 18 (1998) 1267
7. Lin C.C., Hsu C.H., Chen J., Tsai T.C., Cheng A.L., and Pu Y.S. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Anticancer Res 21 (2001) 1385
8. Poon M.A., O'Connell M.J., Moertel C.G., Wieand H.S., Cullinan S.A., Everson L.K., et al. Biochemical modulation of fluorouracil:. evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7 (1989) 1407
9. Nishiyama M., Yamamoto W., Park J.S., Okamoto R., Hanaoka H., Takano H., et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 5 (1999) 2620
10. Lin C.C., Hsu C.H., Huang C.Y., Cheng A.L., Chen J., Vogelzang N.J., et al. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma-an effective regimen with low toxicity. Cancer 106 (2006) 1269
11. Klaassen U., Wilke H., Weyhofen R., Harstrick A., Eberhardt W., Muller C., et al. Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. Anticancer Drugs 9 (1998) 203
12. Kollmannsberger C., Quietzsch D., Haag C., Lingenfelser T., Schroeder M., Hartmann J.T., et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83 (2000) 458
13. Roth B.J., Dreicer R., Einhorn L.H., Neuberg D., Johnson D.H., Smith J.L., et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium. a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12 (1994) 2264
14. Perez E.A., Vogel C.L., Irwin D.H., Kirshner J.J., and Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19 (2001) 4216
15. Pu Y.S., Chen J., Huang C.Y., Guan J.Y., Lu S.H., and Hour T.C. Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells. J Urol 166 (2001) 2082
16. Rowinsky E.K., Gilbert M.R., McGuire W.P., Noe D.A., Grochow L.B., Forastiere A.A., et al. Sequences of taxol and cisplatin. a phase I and pharmacologic study. J Clin Oncol 9 (1991) 1692
17. Burch P.A., Richardson R.L., Cha S.S., Sargent D.J., Pitot H.C., Kaur J.S., et al. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol 164 (2000) 1538
18. Dreicer R., Manola J., Roth B.J., Cohen M.B., Hatfield A.K., and Wilding G. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium. an Eastern Cooperative Oncology Group Study. J Clin Oncol 18 (2000) 1058
19. Kano Y., Akutsu M., Tsunoda S., Ando J., Matsui J., Suzuki K., et al. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74 (1996) 704
20. Bellmunt J., Guillem V., Paz-Ares L., Gonzalez-Larriba J.L., Carles J., Batiste-Alentorn E., et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium Spanish Oncology Genitourinary Group. J Clin Oncol 18 (2000) 3274
21. Bajorin D.F., McCaffrey J.A., Dodd P.M., Hilton S., Mazumdar M., Kelly W.K., et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. final report of a phase II trial evaluating two dosing schedules. Cancer 88 (2000) 1671
22. Pectasides D., Glotsos J., Bountouroglou N., Kouloubinis A., Mitakidis N., Karvounis N., et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer. a phase II trial. Ann Oncol 13 (2002) 243
23. Hainsworth J.D., Meluch A.A., Litchy S., Schnell F.M., Bearden J.D., Yost K., et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 103 (2005) 2298
24. Hussain M., Vaishampayan U., Du W., Redman B., and Smith D.C. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19 (2001) 2527